Cagrilintide / Semaglutide Blend — reference
Fixed weekly combination of an amylin analog and a GLP-1 agonist (CagriSema), studied for weight management.
Regulatory status
Investigational. Not FDA-approved. Novo Nordisk has filed an NDA with the FDA and it was under review at the time of writing — verify current status.
Reported cautions
Pharmacokinetics
Published figures give an elimination half-life of Reflects both components (~7d cagrilintide, ~7d semaglutide). Combination behaves pharmacokinetically as two independent long-acting agents.
This figure is tagged Clinical trial in our evidence system. This figure comes from published human trial data rather than an approved label. It is real data, but it has not been through regulatory review, and the compound may not be approved for any use. You can see the shape this implies between doses in the Half-Life Visualizer, and compare it against every other compound in the Half-Life Data Table. Our sourcing page explains what each tier means.
Remember that an estimated curve is a model built from a population figure, not a measurement of your blood. Individual clearance varies, and for depot injections the figure describes release from the injection site rather than the compound clearing. Half-life explained →
What Peptide Plug does and does not publish
This page carries regulatory status, general context and published pharmacokinetics. It carries no dose, frequency or cycle information — that is a deliberate editorial line, because dosing is a clinical decision rather than reference data. We also do not sell, supply, source or link to vendors for any compound.
Frequently asked
Is Cagrilintide / Semaglutide Blend FDA-approved?
What is the half-life of Cagrilintide / Semaglutide Blend?
How reliable is that half-life figure?
What cautions are associated with Cagrilintide / Semaglutide Blend?
Does Peptide Plug publish dosing for Cagrilintide / Semaglutide Blend?
Does Peptide Plug sell Cagrilintide / Semaglutide Blend?
Related tools
Free, no account required.